Upstream Bio, Inc. (UPB) — Stock Score Summary

Upstream Bio, Inc. (UPB) has a MoatMap StockRank of 5/100 based on Quality (35/100), Value (38/100), and Momentum (9/100) factor scores. The current signal is STRONG SELL.

Upstream Bio, Inc. is a biotechnology company focused on discovering and developing novel therapeutics for inflammatory and immunological diseases. The company's competitive moat is built upon its proprietary drug candidates, designed to target specific pathways involved in various immune-mediated conditions, addressing critical unmet needs in these therapeutic areas. Upstream Bio is an emerging biopharmaceutical firm committed to advancing immunology research.

Key Financial Metrics

Price$8.32
Market Cap$453M
P/E (Forward)-2.72
Price/Book1.31
Return on Equity-41.8%
Return on Invested Capital-47.1%
Debt/Equity0.37
Gross Margin100.0%
Operating Margin-4218.1%
Revenue Growth82.7%
Free Cash Flow$-90M

Upstream Bio, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Upstream Bio, Inc.’s (UPB) StockRank?
MoatMap’s StockRank for Upstream Bio, Inc. (UPB) is 5/100, with a Strong Sell signal. It is a composite of Quality (35), Value (38), and Momentum (9) factor ranks across MoatMap’s 19,000+ stock universe.
Does Upstream Bio, Inc. have an economic moat?
Upstream Bio, Inc. (UPB) has a Quality factor score of 35/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Upstream Bio, Inc. a buy, hold, or sell?
MoatMap’s current signal for Upstream Bio, Inc. (UPB) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Upstream Bio, Inc. in?
Upstream Bio, Inc. (UPB) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksUPB deep dive reportAI ChampionsHow we score stocksSense-check another stock